CNTX Company Profile and Key Details

Q: Who are the executives of CNTX?

Mr. Christopher Beck M.B.A.Senior Vice President of OperationsDr. Felix Kim Ph.D.Co-founder & Chair of Scientific Advisory BoardDr. Tarek Sahmoud M.D., Ph.D.Chief Medical OfficerMr. Alex C. Levit Esq.Chief Legal Officer & Corporation Sec.Ms. Jennifer Minai-AzaryChief Financial Officer & TreasurerDr. Evan G. DickSenior Vice President of R&DMr. Martin A. LehrCo-Founder, Pres, Chief Executive Officer & DirectorMs. Elizabeth Nemchik CPAController

NASDAQ : CNTX

Context Therapeutics

$2.48

0.09+3.77%

At Close 4:00 PM

69.46

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Context Therapeutics Inc. (CNTX) stock surged +3.77%, trading at $2.48 on NASDAQ, up from the previous close of $2.39. The stock opened at $2.40, fluctuating between $2.38 and $2.51 in the recent session.

Stock Snapshot

2.39

Prev. Close

227.86M

Market Cap

2.38

Day Low

-5.9

P/E Ratio

-0.42

EPS (TTM)

-1.32

Cash Flow per Share

2.4

Open

91.88M

Number of Shares

2.51

Day High

65.57%

Free Float in %

0.74

Book Value

308.68K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
May 12, 2026	2.40	2.51	2.38	2.48	308.78K
May 11, 2026	2.38	2.47	2.32	2.39	468.45K
May 08, 2026	2.33	2.40	2.27	2.38	537.58K
May 07, 2026	2.39	2.39	2.30	2.33	351.08K
May 06, 2026	2.44	2.44	2.32	2.41	506.08K
May 05, 2026	2.34	2.45	2.31	2.44	593.96K
May 04, 2026	2.27	2.39	2.27	2.30	631.49K
Apr 30, 2026	2.34	2.36	2.26	2.36	624.32K
Apr 29, 2026	2.51	2.51	2.24	2.34	792.92K
Apr 28, 2026	2.35	2.54	2.32	2.51	1.04M
Apr 27, 2026	2.26	2.36	2.17	2.34	1.66M
Apr 23, 2026	2.39	2.42	2.22	2.32	1.21M
Apr 22, 2026	2.37	2.42	2.32	2.41	623.55K
Apr 21, 2026	2.25	2.43	2.23	2.37	1.19M
Apr 20, 2026	2.43	2.51	2.24	2.26	988.74K
Apr 17, 2026	2.31	2.45	2.31	2.43	1.2M
Apr 16, 2026	2.51	2.52	2.26	2.29	929K
Apr 14, 2026	2.46	2.53	2.38	2.51	1.07M
Apr 13, 2026	2.48	2.49	2.32	2.46	1.1M
Apr 10, 2026	2.60	2.68	2.47	2.49	519.02K

Contact Details

Philadelphia, PA 19103

United States

https://www.contexttherapeutics.com 267 225 7416

About Company

Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers. The company is also developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for gynaecologic cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

Stock Peers

ARGX

-0.47-0.06%

argenx SE$812.81 REGN

10.64+1.49%

Regeneron Pharmaceuticals, Inc.$723.41 UTHR

11.86+2.08%

United Therapeutics Corporation$581.74 MDGL

13.23+2.66%

Madrigal Pharmaceuticals, Inc.$510.26 VRTX

13.12+3.01%

Vertex Pharmaceuticals Incorporated$448.29 PRAX

11.39+3.43%

Praxis Precision Medicines, Inc.$343.20 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 KRYS

-2.57-0.82%

Krystal Biotech, Inc.$310.31 ALNY

7.19+2.52%

Alnylam Pharmaceuticals, Inc.$292.03 ASND

-1.02-0.43%

Ascendis Pharma A/S$237.65

Company Overview

Context Therapeutics Inc. (NASDAQ:CNTX) closed at $2.48 USD, gaining $0.09 (3.77%) from the previous close of $2.39. The stock is currently mid-range between its 52-week high and low $0.49 and $3.62. With a market capitalization of about $227.86 million, Context Therapeutics Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.57). Key stats such as the average daily volume over the past year has been around 864.48 thousand shares, volume is running light vs its 52-week average. Headquartered in Philadelphia, PA, Context Therapeutics Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Martin A. Lehr, the company employs approximately 12 people and listed since October 20, 2021. Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States.

Technical Performance

Short-term trend indicators are bearishly aligned (SMA20 -3.27%, SMA50 23.82%, SMA200 101.29%). The stock’s 14-day RSI is 54.24 (neutral), while the ATR of 0.21 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -20.0% below its high and over 365.31% above its low. Average 10-day trading volume of 485.35 thousand shares is below the 3-month average of 822.46 thousand, indicating normal recent market interest.

Valuation Metrics

Context Therapeutics Inc. trades at a P/E ratio of -5.87, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 4.52 trading at moderately above to book value. The P/FCF stands at -6.94, also below market averages.

Dividend & Fair Value

Context Therapeutics Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.69. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Context Therapeutics Inc. generated EPS of -$0.28 over the past year. Five-year average earnings growth is 4.72%. Wall Street analysts project EPS growth of 4.76% annually over the next five years. The latest quarter delivered EPS of -$0.09. The next quarter is forecast at -$0.10. Next year's EPS is expected at $13.16. Analyst sentiment is bullish. Analyst rating data shows there are 2 Strong Buy ratings, 9 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $9.00 to $4.00. The high target offers 262.9% upside. The low target suggests 61.29% downside. The mean target is $6.64. This offers 167.74% upside. Context Therapeutics Inc. earnings surprise history is a mixed track record. The quarter that ended May 06, 2026, missed forecasts by -25.0%. The prior quarter beat by 27.27%. Over the last six quarters, Apple has recorded several small beats. These include -20.0% in March 20, 2025.

Shareholding & Insider Activity

Context Therapeutics Inc. has 89.70 million shares outstanding. The public float is 37.70 million shares, elevated short interest at 0.71% of float. This equals 521.19 thousand shares. The short ratio is 3.11 days. Institutional investors hold 77.52% of the float. Insiders own 1.45%. Lehr Martin A. holds 920.19 thousand shares, Minai-Azary Jennifer Lynn has 80.01 thousand shares and Levit Alex C. has 29.00 thousand shares.

Financial & Profitability Overview

Over the trailing twelve months, Context Therapeutics has not generated any revenue. Returns are negative, with ROA at -149.19% and ROE at -201.87%.
On valuation metrics, Context Therapeutics trades at a P/E of -5.87, P/S of 0.00 and P/B of 4.52. The current ratio is 8.96 and quick ratio is 8.96. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -22404.00 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.01, supported by a cash flow-to-debt ratio of -116.09.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Context Therapeutics posted revenue of $0.00, down slightly from $0.00 in the prior quarter. Gross profit was - $12.04K (margin 0.00%). Operating income was - $25.07M (margin 0.0%). Net income was- $23.96M (EPS - $1.50).
The company ended the quarter with $14.45M in cash and short-term investments, a total debt of $0.00, and net debt of - $14.45M. Total assets were $16.06M, with equity of $11.87M. Financials further reflected weakness, with operating cash flow of - $21.05M, free cash flow of - $21.05M, and capital expenditures of $0.00.

Price Forecast & Outlook

Our AI price prediction model suggests that Context Therapeutics Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -2.42%, with price expected at $2.42 by May 26, 2026, within a range of $2.28 to $2.55 3-Month Outlook: Projected rise of 29.44%, reaching $3.21 by August 10, 2026, with a range of $3.14 to $3.29. 1-Year Outlook: Projected gain of 879.44%, with price at $24.29 by May 12, 2027, within a range of $27.32 to $28.18.

Key Takeaways

Context Therapeutics Inc. (NASDAQ:CNTX) shares are flat 4.76% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Context Therapeutics Inc. trading at a premium to the broader market with a P/E of -5.87. Analyst sentiment is bullish, with the majority of ratings in Overweight territory and a mean price target of $6.58, suggesting 165.32% upside. Our AI forecast model points to short-term weakness (-2.42% over two weeks), a medium-term rise (29.44% over three months), and a longer-term gain (879.44% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Context Therapeutics Inc. (CNTX) stock price?

Context Therapeutics Inc. (NASDAQ: CNTX) stock price is $2.48 in the last trading session. During the trading session, CNTX stock reached the peak price of $2.51 while $2.38 was the lowest point it dropped to. The percentage change in CNTX stock occurred in the recent session was 3.77% while the dollar amount for the price change in CNTX stock was $0.09.

CNTX's industry and sector of operation?

The NASDAQ listed CNTX is part of Biotechnology industry that operates in the broader Healthcare sector. Context Therapeutics Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of CNTX?

Mr. Christopher Beck M.B.A.
Senior Vice President of Operations
Dr. Felix Kim Ph.D.
Co-founder & Chair of Scientific Advisory Board
Dr. Tarek Sahmoud M.D., Ph.D.
Chief Medical Officer
Mr. Alex C. Levit Esq.
Chief Legal Officer & Corporation Sec.
Ms. Jennifer Minai-Azary
Chief Financial Officer & Treasurer
Dr. Evan G. Dick
Senior Vice President of R&D
Mr. Martin A. Lehr
Co-Founder, Pres, Chief Executive Officer & Director
Ms. Elizabeth Nemchik CPA
Controller

How CNTX did perform over past 52-week?

CNTX's closing price is 406.12% higher than its 52-week low of $0.49 where as its distance from 52-week high of $3.62 is -31.49%.

How many employees does CNTX have?

Number of CNTX employees currently stands at 12.

Link for CNTX official website?

Official Website of CNTX is: https://www.contexttherapeutics.com

How do I contact CNTX?

CNTX could be contacted at phone 267 225 7416 and can also be accessed through its website. CNTX operates from 2001 Market Street, Philadelphia, PA 19103, United States.

How many shares of CNTX are traded daily?

CNTX stock volume for the day was 308.68K shares. The average number of CNTX shares traded daily for last 3 months was 864.48K.

What is the market cap of CNTX currently?

The market value of CNTX currently stands at $227.86M with its latest stock price at $2.48 and 91.88M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	12
Beta	1.83
Sales or Revenue	$0.00
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

CNTX Company Profile and Key Details

Context Therapeutics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Financial & Profitability Overview

Quarterly Financial Highlights

Shareholding & Insider Activity

Technical Performance

Earnings & Analyst Outlook

Valuation Metrics

Company Overview

Dividend & Fair Value

Price Forecast & Outlook

Key Takeaways